Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleOncology

Cerenkov Radiation–Induced Photoimmunotherapy with 18F-FDG

Yuko Nakamura, Tadanobu Nagaya, Kazuhide Sato, Shuhei Okuyama, Fusa Ogata, Karen Wong, Stephen Adler, Peter L. Choyke and Hisataka Kobayashi
Journal of Nuclear Medicine September 2017, 58 (9) 1395-1400; DOI: https://doi.org/10.2967/jnumed.116.188789
Yuko Nakamura
1Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadanobu Nagaya
1Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuhide Sato
1Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuhei Okuyama
1Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fusa Ogata
1Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Wong
1Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Adler
2Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., National Cancer Institute Campus at Frederick, Frederick, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter L. Choyke
1Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hisataka Kobayashi
1Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Absorption spectrum of IRDye 700DX.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Evaluation of in vitro UV-A PIT (*P < 0.05, **P < 0.01, vs. untreated control). (A) Percentage of surviving cells decreased in light dose-dependent manner although 50% of A431-luc cells died when pan-IR700 alone without UV-A light was administered. (B) Propidium iodide staining showed membrane damage in MDAMB468-luc cells induced by UV-A PIT although significant cytotoxicity associated with UV-A light alone was observed. (C) With tra-IR700, percentage of surviving 3T3/HER2-luc cells decreased in light dose-dependent manner.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Evaluation of in vitro CR-PIT using 18F-FDG. (A) When A431-luc cells were used, suppression of luciferase activity in cells was seen in CR-PIT and the degree of suppression increased in a dose-dependent manner. (B) When MDAMB468-luc cells were used, CR-PIT did not significantly change the level of luciferase activity compared with 18F-FDG alone. (C) When 3T3/HER2-luc cells were used, CR-PIT also did not significantly change the level of luciferase activity compared with 18F-FDG alone.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    In vivo effect of CR-PIT on A431-luc tumor. (A) CR-PIT regimen is shown. (B) 18F-FDG PET imaging of tumor-bearing mice. Tumor showed high accumulation of 18F-FDG (arrow). (C) Bioluminescence imaging of tumor-bearing mice.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    In vivo effect of CR-PIT on A431-luc tumor. (A) Luciferase activity ratio was suppressed in CR-PIT group compared with control group. (B) Significant suppression of luciferase activity ratio was seen in CR-PIT group compared with control group. NS = not significant.

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    Resected tumors stained with hematoxylin and eosin. Cellular necrosis and microhemorrhage were seen within a background of live but damaged tumor cells after CR-PIT whereas little damage was observed in tumors receiving 18F-FDG administration alone. No obvious damage was observed in the tumor receiving only APC but no 18F-FDG administration.

Additional Files

  • Figures
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (9)
Journal of Nuclear Medicine
Vol. 58, Issue 9
September 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cerenkov Radiation–Induced Photoimmunotherapy with 18F-FDG
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Cerenkov Radiation–Induced Photoimmunotherapy with 18F-FDG
Yuko Nakamura, Tadanobu Nagaya, Kazuhide Sato, Shuhei Okuyama, Fusa Ogata, Karen Wong, Stephen Adler, Peter L. Choyke, Hisataka Kobayashi
Journal of Nuclear Medicine Sep 2017, 58 (9) 1395-1400; DOI: 10.2967/jnumed.116.188789

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cerenkov Radiation–Induced Photoimmunotherapy with 18F-FDG
Yuko Nakamura, Tadanobu Nagaya, Kazuhide Sato, Shuhei Okuyama, Fusa Ogata, Karen Wong, Stephen Adler, Peter L. Choyke, Hisataka Kobayashi
Journal of Nuclear Medicine Sep 2017, 58 (9) 1395-1400; DOI: 10.2967/jnumed.116.188789
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology

  • The Evolving Role of FDG-PET/CT in Assessing Primary Cutaneous Lymphoma
  • Molecular imaging of Renal clear cell carcinoma subtypes as metabolic diseases
  • Role of PET/CT in the management of multiple myeloma
Show more Oncology

Basic

  • Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
  • Optical Navigation of the Drop-In γ-Probe as a Means to Strengthen the Connection Between Robot-Assisted and Radioguided Surgery
  • Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression
Show more Basic

Similar Articles

Keywords

  • Photoimmunotherapy
  • UV-A light
  • Cerenkov radiation
  • 18F-FDG
SNMMI

© 2025 SNMMI

Powered by HighWire